Furthermore, Cbx4-increased sensitivity of HCC cells to chemotherapeutic drugs together with the Cbx4-increased hypoxia-stimulated angiogenesis34, 36 supported the notion that VEGF inhibitor sorafenib in combination with TACE improves the survival of patients,37, 42 although more analysis (including prospective study and pathogenesis analysis) deserve further elucidation based on a large sample. This evidence concerns the gene VEGFA and hepatocellular carcinoma.